AlphAIAlphAI — Financial news for AI agents
quiverquant.comOCT 11 min read$RMD

RESMED INC ($RMD) CEO 2026 Pay Revealed

ResMed Inc. ($RMD) CEO Michael Farrell's 2026 compensation is estimated at $16.2M, up 9.43% from 2025. Insiders sold $RMD shares 7 times in 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing their positions. Analysts have issued mixed price targets, with a median of $268.

Original reporting
quiverquant.com
Published Oct 1, 2026, 10:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 2:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RESMED INC ($RMD) CEO 2026 Pay Revealed — source image
Source · quiverquant.com
Decision brief

The 30-second read

$RMDBearishLow
01

Why it matters

The new compensation data and insider sales provide fresh insight into management incentives and possible market perception.

02

Market read

The filing offers new quantitative details that may influence short‑term trading decisions on RMD.

03

What to watch

Potential upcoming product launches or contract wins for ResMed could mitigate negative sentiment from insider sales.

Relevance 5/10Novelty 5/10Timing: post‑filing today

Background

ResMed (RMD) is a leading provider of cloud‑connected medical devices for sleep apnea and respiratory care.

Company-level read

Ticker impact

$RMDBearishMedium confidence
Context

SEC DEF14A filing shows CEO Michael Farrell's 2026 compensation rose 9.43% and details multiple insider sales.

Expected impact

likely downward pressure as market prices in insider sell activity and compensation increase

Evidence & confidence

The filing reveals five sales by the CEO totaling over 24,000 shares and a 9% pay increase, which historically can trigger short‑term sell‑offs.

Market effects

Sector

Limited; reflects broader scrutiny of executive compensation in medical‑device sector.

Regional

U.S. market focus, no regional spillover.

Global

Low; company‑specific news.

Counterpoint

What could challenge this read

Some investors may view the compensation rise as a sign of confidence in growth prospects, offsetting sell pressure.

Key entities

  • Executive
    Michael Farrell

    Chairman and CEO of ResMed, reported compensation and insider sales.

Read at source← All news

Related articles

SEP 28
$RMDMed

Health Check: No 'Wharfie Time' curse as healthcare stocks kick away from the pack

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

stockhead.com.au5 min
SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
SEP 16
$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min
SEP 15
$RMDHighAI 8/10

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

investing.com2 min